Latest Intellectual Property News

Codrus Minerals has completed its acquisition of EdgeMet, adding copper and molybdenum exploration projects in Queensland and Peru alongside early-stage technology from Rice University. The transaction was funded with 230 million shares, 60 million performance rights and A$100,000 in upfront cash.

FortifAI has emerged from its first year as an AI infrastructure company with $20.4 million in cash, but a $29 million statutory loss and sharply lower gaming revenue. The company now needs to turn NOL8’s early testing and partnerships into commercial adoption before its cash-backed growth strategy faces a harder test.

MCS Services has completed the sale of its Traffic Business and now has no operating business, while its ASX securities remain suspended pending a possible recompliance transaction. The company reported $1.77 million in cash at 30 June 2026, but also faces a $495,000 legal settlement and no recurring operating revenue.

Energy Technologies has reported a deeper FY2026 loss, collapsing revenue and a $22.65 million equity deficiency, with its auditor flagging material uncertainty over the group’s ability to continue as a going concern. A five-year laser optics licence offers a potential new revenue path, but it remains conditional on development and future commercial sales.

Mayne Pharma has settled patent litigation with Sun Pharma over IMVEXXY, establishing 21 October 2032 as the agreed potential generic entry date, subject to court approval. The settlement involves no upfront payment, while one further Paragraph IV dispute remains unresolved.

Paradigm Biopharmaceuticals has entered voluntary administration after its pivotal Phase 3 trial produced an interim efficacy result below the threshold required for continuation. The company’s securities will remain suspended while administrators assess its viability, liabilities and possible restructuring options.

Papyrus Australia has produced a second batch of TBS board samples, expanded pulp capacity in Adelaide and secured additional funding as it moves towards commercial supply. The progress comes with testing still incomplete and an estimated 4.87 months of funding available.

Identitii’s BNDRY platform gained customers and recurring revenue in FY26, but the company ended the year with just $107,483 in cash, negative net assets and a material uncertainty over its ability to continue as a going concern. A subsequent convertible note facility provides a committed $5 million, while access to a further $15 million remains conditional.

TrivarX has made Stabl-Im its central development bet, but the ASX-listed health technology company also reported an $8.76 million FY2026 loss and an auditor-flagged material uncertainty over its ability to continue without further funding. The planned Phase 1 study remains subject to regulatory, ethics and operational clearances.

Neuren says its partner Acadia has received a US Notice of Allowance for a trofinetide patent that could protect weight-banded dosing through 28 March 2041. The patent has not yet formally issued, but the allowance could extend US protection by almost five years beyond the existing method-of-use patent.

SciDev Limited (ASX:SDV) finished FY26 with a sharp annual earnings decline, but a leaner business and stronger second-half performance offer a potential reset. Revenue fell 17% and underlying EBITDA dropped 49%, while the company exited loss-making international operations and rebuilt net cash to $6.8 million.

Argent BioPharma has secured exclusive commercialisation rights to selected Tollovir, Tollovid and NutraVir antiviral products in a worldwide deal excluding China. The agreement adds a new commercial pillar alongside CimetrA®, but does not itself grant pharmaceutical development rights or establish clinical efficacy.